



# Biotech Daily

Tuesday November 19, 2019

*Daily news on ASX-listed biotechnology companies*

- \* **ASX UP, BIOTECH DOWN: ACTINOGEN UP 27%; ONCOSIL DOWN 19%**
- \* **MICRO-X RAISES \$16.5m IN PLACEMENT; AMENDS THALES LOAN**
- \* **HEMIDEINA RAISES \$4m FOR WIRELESS HEARING IMPLANT**
- \* **GENETIC SIGNATURES SHARE PLAN RAISES \$2.5m, TOTAL \$37.5m**
- \* **REGENEUS SHORTFALL RAISES \$755k, TOTAL \$5.5m**
- \* **ALCIDION LAUNCHES MOBILE ELECTRONIC MEDICAL RECORDS**
- \* **ONCOSIL SUBMITS UPDATED CE MARK REPORT**
- \* **MEDLAB NRGBIOTIC DEPRESSION TRIAL ON-TRACK**
- \* **MAYNE LICENCES GENERIC DERMATOLOGY PRODUCT FOR US**
- \* **OSTEOPORE, CHINA'S BOAO YILING NOSE JOB DEAL**
- \* **ADMEDUS PLEADS SCHULTZ TO ASX 48% QUERY**
- \* **BENITEC 10-TO-1 ADS CONSOLIDATION FOR NASDAQ COMPLIANCE**
- \* **WASHINGTON PATTINSON, BRICKWORKS DILUTED TO 19.9% IN PALLA**
- \* **COGSTATE APPOINTS KEN BILLARD CHIEF COMMERCIAL OFFICER**

## MARKET REPORT

The Australian stock market was up 0.7 percent on Tuesday November 19, 2019, with the ASX200 up 47.4 points to 6,814.2 points. Nine of the Biotech Daily Top 40 stocks were up, 23 fell, seven traded unchanged and one was untraded. All three Big Caps were up.

Actinogen was the best, up 1.2 cents or 27.3 percent to 5.6 cents, with 65.4 million shares traded. Paradigm climbed 11.6 percent; Prescient improved 10 percent; Compumedics was up nine percent; LBT was up three percent; Nanosonics and Osprey rose more than two percent; Cochlear, Proteomics and Resmed rose more than one percent; with CSL and Starpharma up by less than one percent.

Oncosil led the falls, down four cents or 19.05 percent to 17 cents, with 9.8 million shares traded. Pharmaxis fell 10.4 percent; Amplia lost 8.3 percent; Alterity and Impedimed were down more than seven percent; Antisense and Kazia fell more than five percent; Patrys was down 4.8 percent; Clinuvel, Ellex, Polynovo and Pro Medicus were down more than three percent; Avita, Cynata and Next Science shed more than two percent; Genetic Signatures, Immutep, Imugene, Medical Developments and Telix were down more than one percent; with Cyclopharm, Neuren and Orthocell down by less than one percent.

## MICRO-X

Micro-X says it has raised \$16.5 million in an “oversubscribed” placement at 20 cents a share, and has amended its loan with the Paris-based Thales Group.

Micro-X said the share price was a 25.0 percent discount to the last traded price of 25 cents on November 1, 2019, and the placement shares would be issued in two tranches, the first by November 25, 2019 and the remainder pending shareholder approval.

Micro-X said two directors had subscribed for \$350,000 worth of shares, subject to shareholder approval.

Micro-X managing-director Peter Rowland said the funds would be used further the DRX Revolution Nano miniature x-ray system roll-out and increase sales.

“We are also able to progress towards completing the first-generation version of the Rover [mobile military x-ray system] and attracting two key military customers within the next 12 months,” Mr Rowland said.

“We can also fully support our engagement with Thales on the [counter-terrorism Mobile backscatter imager] and future airport screening products,” Mr Rowland said.

Micro-X made no mention of a share purchase plan for retail investors.

The company has been in a trading halt and voluntary suspension for a “capital management review” and capital raising (BD: Nov 4, 6, 11, 2019).

According to the Australian Securities and Investments Commissions Regulatory Guide 125, titled ‘Share and interest purchase plans’, relief for share purchase plans is not available for companies that have been suspended for more than five days.

Sub-section 31 of the guide says ASIC could “consider granting case-by-case or individual relief to permit an issuer to offer a purchase plan even when the shares or interest have been suspended for more than five days”.

Separately, Micro-X said that following a review of its notice of annual general meeting, the ASX determined that the \$10 million convertible loan agreement with the Thales was a “convertible security” and considered part of Micro-X’s placement capacity under Listing Rule 7.1 (BD: Jul 2, 2019).

Micro-X said it had amended the Thales loan agreement so that the convertible security would need shareholder approval to take effect and a meeting to approve the convertible security was expected to be held by December 31, 2019.

Micro-X fell one cent or four percent to 24 cents.

## HEMIDEINA

Melbourne’s Hemideina says it has raised \$4 million in a series A funding round to develop and commercialize its Hera wireless implant.

Hemideina said the it was the second round of equity financing and followed the validation of its core mechanical signal processing technology.

The company said it had achieved “several significant technical milestones” and was on-track with its development and commercialization strategy.

Hemideina said the funds would allow it to advance the Hera implant towards pre-clinical testing, extend the company’s intellectual property portfolio and expand the commercialization team.

Hemideina chief executive officer Dr Elizabeth Williams said the investment community had “demonstrated a strong understanding of our proposition and its inherent value”.

“We have made substantial progress this year and we are moving closer to realizing our clinical and commercial objectives,” Dr Williams said.

The company said the capital raise was managed by Melbourne advisory firm Henslow. Hemideina is a private company.

## GENETIC SIGNATURES

Genetic Signatures says its share plan at 98 cents a share was “oversubscribed” and has been expanded to \$2.5 million taking the total raised to \$37.5 million

In October, Genetic Signatures said it raised \$35 million in a placement at 98 cents a share and hoped a share plan would raise a further \$2 million (BD: Oct 28, 2019).

Today, the company said the plan was oversubscribed by more than 50 percent and following the expansion to \$2.5 million it would scale-back applications pro-rata.

Genetic Signatures fell 1.5 cents or 1.3 percent to \$1.14.

## REGENEUS

Regeneus says it has raised \$755,029 by placing 9,437,872 shortfall shares at eight cents each to a Japanese institutional investor, taking the total raised to \$5.5 million.

In August, Regeneus said it has raised \$2.34 million in a private placement, and a further \$620,157 of a hoped for \$3.2 million in its one-for-six rights issue at eight cents a share, with \$1.8 million underwritten by directors and three months to place the remaining shortfall shares (BD: Aug 1, 30, 2019).

Regeneus chief executive officer Leo Lee said that “the completion of the non-renounceable rights issue, together with our streamlined internal operations and pending Progenza licencing deal in Japan, Regeneus will be sufficiently funded to [begin] commercialization in Japan”.

Regeneus was up 2.9 cents or 43.9 percent to 9.5 cents with two million shares traded.

## ALCIDION GROUP

Alcidion says it has launched its clinical smartphone application Miya Memre, a mobile electronic medical record to assist clinicians their caseloads and patient histories.

Alcidion said that Miya Memre was being trialled at Australian health services to measure its effect within local clinical systems.

The company said the Miya Memre provided clinicians in high-intensity areas, such as emergency departments, test results and risk indicators to enhance decision-making.

Alcidion chief medical officer Dr Malcolm Pradhan said that “by giving clinicians access to the information they need to make decisions and take action we help them deliver the best possible care and outcomes for their patients”.

Alcidion was up two cents or 10.5 percent to 21 cents with 6.0 million shares traded.

## ONCOSIL MEDICAL

Oncosil says it will submit plans for the final review of its Oncosil device to the British Standards Institute for its Conformité Européene (CE) mark application.

In March, the company’s share price fell as much as 86.9 percent on news that the British Standards Institute’s (BSI) clinical oversight committee found “insufficient clinical benefit” to approve its pancreatic cancer radiotherapy (BD: Mar 25, 2019)

Last month, the company said it had submitted an updated clinical evaluation report to the BSI following a request from the BSI and the committee (BD: Oct 11, 29, 2019).

Today, the company said it held “a positive and constructive meeting” with the Institute on its post market surveillance plan and post market clinical follow-up program.

Oncosil said it would “finalize its commercialization plans in anticipation of CE Marking approval in the coming months”.

Oncosil fell four cents or 19.05 percent to 17 cents with 9.8 million shares traded.

## MEDLAB CLINICAL

Medlab says its 150-patients phase II NRGBiotic depression trial has treated 90 patients and shown “a potential efficacious trend-line”.

In 2016, Medlab said it would begin a double-blind, placebo-controlled, phase IIa trial of its bacteria-based NRGBiotic anti-depression therapy to target the gut-brain axis, after a phase I trial of patients who had been prescribed anti-depressants for an average of two and a half years, demonstrated improvement of 80 and 90 percent in two separate cohorts (BD: Aug 30, 2016).

In 2017, the company said it had ethics approval for the phase IIa trial with the Brisbane-based Queensland University of Technology, and had been granted a patent for NRGBiotic as an adjunct treatment for depression (BD: Mar, 27, Sep 18, 2017).

Earlier this year, Medlab said the University had recruited 32 patients in the second round of recruitment for the trial of its probiotic NRGBiotic with anti-depressants for depression (BD: Feb 14, 2019).

Today, the company said that the trial may only need 130 of the 150 patients planned for the trial to reach a statistically significant outcome.

Medlab chief executive officer Dr Sean Hall said that “the study timelines are progressing as planned, and at this point the trial should complete ahead of expectations”.

Medlab was up one cent or 2.7 percent to 38 cents.

## MAYNE PHARMA

Mayne says it has licenced the rights to a generic topical dermatology product from the Mumbai, India-based Encube Ethicals, for distribution in the US.

Mayne said the generic dermatology product had been filed with the US Food and Drug Administration and it expected approval next year.

The company said that for the year to September 30, the products had sales of more than \$US40 million (\$A58,853,300).

Mayne chief executive officer Scott Richards said that this product was “the third dermatology product we have licenced [since June 30, 2019]”.

Mayne fell half a cent or 0.9 percent to 56 cents with five million shares traded.

## OSTEOPORE

Osteopore says China’s Boao Yiling Life Care Centre will use its products for rhinoplasty procedures, with an initial purchase order from Sinopharm Group.

Osteopore said it would cooperate with the Hianan Province-based Boao Yiling to establish a training base for using Osteopore’s patented 3D printed bioresorbable products for natural bone healing in rhinoplasty, or nose reconstruction procedures.

The company said that Boao Yiling would help bring Osteopore products into China and collect data to secure registration from the Chinese National Medical Products Administration.

Osteopore said that through its deal with Boao Yiling, it had received a purchase order from the Chinese government-run Sinopharm Group to buy Osteopore products for use in Boao Yiling.

The company said that products were sold to Sinopharm at “commercial rates” but revenues from this sale were not considered material.

Osteopore was up five cents or 6.1 percent to 87 cents.

### [ADMEDUS](#)

Admedus has told the ASX that it is not aware of any information it has not announced which, if known, could explain recent trading in its securities.

The ASX said the company's share price rose 47.89 percent from 7.1 cents to 10.5 cents "in the last few days", and noted a "significant increase" in the trading volume from November 15 to 19, 2019.

Admedus closed up 1.9 cents or 24.05 percent at 9.8 cents with 4.4 million shares traded.

### [BENITEC BIOPHARMA](#)

Benitec says it will implement a 10-to-one consolidation of its Nasdaq-listed American depository shares to ensure its share price is above the minimum \$US1.00 bid price.

In July, Benitec says it received a non-compliance letter from the Nasdaq requiring it to ensure its share price was above \$US1.00 within 180 days (BD: Jul 25, 2019).

Today, the company said it would change the ratio of its American depository shares (ADSs) program from one ADS for 20 ASX shares to one ADS for 200 ASX shares, effective from 18 November 2019.

Benitec fell 0.4 cents or 7.4 percent to five cents with 1.6 million shares traded.

### [PALLA PHARMA \(FORMERLY TASMANIAN POPPY INDUSTRIES ENTERPRISES\)](#)

Washington H Soul Pattinson and Brickworks say their 25,040,465 share-holding in Palla Pharma has been diluted from 23.18 percent to 19.88 percent.

The Sydney-based Washington H Soul Pattinson and Brickworks said they were diluted due to the issue of new shares.

Last week, Palla Pharma raised \$10.1 million in a retail entitlement offer, taking the total raised in its institutional rights offer and two-for-five entitlement offer at 70 cents a share to \$30.7 million (BD: Nov 15, 18, 2019).

Palla was up 2.5 cents or 3.1 percent to 82.5 cents.

### [COGSTATE](#)

Cogstate says it has appointed Ken Billard as chief commercial officer to oversee sales and devise strategies to expand the use of Cogstate solutions in clinical trials.

Cogstate said Mr Billard had 30 years' experience in healthcare and technology, including CRF Health, McKesson HBOC and CB Technologies.

Cogstate was unchanged at 35 cents.